赛诺菲(SNY.O)预计投资将在多个州创造高薪就业岗位。 ...

赛诺菲到2030年将于美国投资至少200亿美元，这将属于研发开支。 ...

赛诺菲将在2030年前至少在美国投资200亿美元，增加科研投入并扩大美国国内生产。 ...

MORRISTOWN, N.J. and CAMBRIDGE, Mass., May 14, 2025 /PRNewswire/ -- Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing.The announcement comes as Sanofi prepares for the potential launch of numerous new first- or best-in-class medicines across many indications in the coming years, aiming to improve the he ...

本届科博会上，赛诺菲以免疫学创新为核心，系统展现了覆盖呼吸系统疾病、皮肤免疫、代谢性疾病等 多个关键疾病领域的突破性疗法。目前，赛诺菲已向中国引入60余种创新药物和疫苗。 中国市场是赛诺菲的第二大市场。赛诺菲一直以全球资源经验赋能本土实践，加速推动医药创新成果转 化与医疗资源可及，深度参与中国科创生态共建。目前，赛诺菲已在北京、上海、成都、苏州设立四大 本土研发中心，构建起覆盖全国的研发网络，中国已参与赛诺菲90%以上的全球研发项目，成为全球研 发布局中的关键力量。 在本土合作方面，赛诺菲携手箕星药业、天境生物等本土生物医药企业，加速推进肿瘤、免疫等前沿疗 法的研发进程；与凯辉基金联合成立专项医药创新基金，加速本土科研成果的商业化转化；与上药控股 等产业伙伴积极探索创新商业模式，持续提升基层医疗服务的可及性。 记者从赛诺菲获悉，该公司在2025年中国北京国际科技产业博览会(以下简称"科博会")携众多全球创新 产品亮相。 作为展示北京国际科技创新中心建设成果的重要平台，本届科博会于5月8日开幕，聚焦生物医药等战略 性新兴产业，吸引了赛诺菲等众多国际化企业参与。赛诺菲以"追寻科学奇迹，共创健康未来"为主题， 着重 ...

新京报讯（记者王卡拉）5月8日，2025年中国北京国际科技产业博览会（以下简称"科博会"）开幕，作 为展示北京国际科技创新中心建设成果的重要平台，本届科博会聚焦生物医药等战略性新兴产业，吸引 了众多国际化企业参与科技交流与合作。全球生物医药企业赛诺菲围绕"追寻科学奇迹，共创健康未 来"主题，携多个关键疾病领域的全球创新产品亮相。 本次参展，赛诺菲着重展示了公司在引领免疫学创新、共筑本土科创生态，以及服务中国患者三大领域 取得的关键成果。展台以免疫学创新为核心，系统展现了覆盖呼吸系统疾病、皮肤免疫、代谢性疾病等 多个关键疾病领域的九大突破性疗法。新京报记者从赛诺菲获悉，截至目前，赛诺菲已向中国引入60余 种创新药物和疫苗，覆盖中国前十大致命疾病中的七种。 展台还重点打造了以"奇迹点亮童年"为主题的患者故事展区。通过沉浸式叙述，将那些被糖尿病、呼吸 道合胞病毒（RSV）感染以及被罕见病困扰的患者们的鲜活经历展示给观众，让他们体会到创新药物和 免疫预防手段不仅是点亮未来的科学之光，更是改变每一个患儿命运的"奇迹"力量。 中国市场是赛诺菲的第二大市场。新京报记者了解到，赛诺菲已在北京、上海、成都、苏州设立四大本 土研 ...

来源：环球网 赛诺菲大中华区总裁施旺表示， "中国是赛诺菲全球重要战略市场之一。我们正在加快多款突破性创新 药物和疫苗产品在中国的落地，进一步夯实从研发到生产、运营一体化的产业链布局与本土创新体系， 并携手本土伙伴，深度融入中国医疗健康事业建设，为培育生物医药新质生产力注入澎湃动能，助力实 现健康中国2030愿景。" 2024年12月，赛诺菲宣布新增10亿欧元投资，用于在京新建胰岛素生产基地，创下公司在华最大单笔投 资记录，进一步彰显了其深耕中国的信心与决心。 目前，赛诺菲已在北京、上海、成都、苏州设立四大本土研发中心，构建起覆盖全国的研发网络。目 前，中国已参与赛诺菲90%以上的全球研发项目，展现出强劲的创新能力，成为全球研发布局中的关键 力量。 5月8日，在2025年中国北京国际科技产业博览会（以下简称"科博会"）开幕首日，赛诺菲携全球创新产 品亮相。作为展示北京国际科技创新中心建设成果的重要平台，本届科博会聚焦生物医药等战略性新兴 产业，吸引了赛诺菲等众多国际化企业参与科技交流与合作。 在本土合作方面，赛诺菲携手箕星药业、天境生物等领先的本土生物医药企业，加速推进肿瘤、免疫等 前沿疗法的研发进程；与凯辉 ...

Core Points - Sobi, in collaboration with the World Federation of Hemophilia (WFH) and Sanofi, has signed a contract to support the WFH Humanitarian Aid Program for up to five years, focusing on medicine donations and financial assistance [1][3] - The commitment includes the donation of up to 100 million international units (IU) of factor therapy annually to be distributed to developing countries [2] - Over the past decade, Sobi and Sanofi have provided one billion IUs of treatment products, benefiting 22,219 individuals with inherited bleeding disorders [3][4] Company Contributions - Sobi and Sanofi's partnership has been ongoing for over ten years, demonstrating a strong commitment to improving care for people with hemophilia globally [1][3] - The new agreement aims to create a predictable and sustainable program that addresses unmet needs and enhances the standard of care for hemophilia [5] - The contributions from Sobi and Sanofi have significantly expanded treatment availability and improved patient outcomes in developing countries [5][6] Humanitarian Aid Program - The WFH Humanitarian Aid Program aims to provide essential support for individuals with inherited bleeding disorders in developing countries, ensuring consistent access to treatment [8] - The program is a collaborative effort that has transformed patient care and elevated the capacity of healthcare professionals worldwide [6][8] - The vision of the WFH is to ensure that all individuals with inherited bleeding disorders have access to necessary care, regardless of their circumstances [9]

Thomas Guslatin Hello, everyone. This is Thomas Guslatin from the Sanofi IR team. Welcome to the Q1 2025 Conference Call for investors and analysts. As usual, you can find the slides on sanofi. com. Please turn to Slide #3, please. Here, we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risks and uncertainties that may cause actual results to differ materially. We encourage y ...

Business Finance Pipeline Appendices Results Q1 2025 April 24, 2025 Business Finance Pipeline Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future ...